{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "def explode_str(df, col, sep):\n",
    "    s = df[col]\n",
    "    i = np.arange(len(s)).repeat(s.str.count(sep) + 1)\n",
    "    return df.iloc[i].assign(**{col: sep.join(s).split(sep)})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_excel(\"vi.xlsx\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = data.head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(156, 4)"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "data['DFO Description']=data['DFO Description'].astype(str)\n",
    "data['Important Sentences_edit']=data['Important Sentences_edit'].astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "str"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(data['Important Sentences_edit'][0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "imp_sen = data['Important Sentences_edit'].to_list()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "imp_sen1 = set(imp_sen) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "142"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(imp_sen1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "def explode_str(df, col, sep):\n",
    "    s = df[col]\n",
    "    i = np.arange(len(s)).repeat(s.str.count(sep) + 1)\n",
    "    return df.iloc[i].assign(**{col: sep.join(s).split(sep)})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import pandas as pd\n",
    "\n",
    "def separate_row(df, column_name):\n",
    "    ls = []\n",
    "    for row_dict in df.to_dict('records'):\n",
    "        for word in re.split('.', row_dict[column_name]):\n",
    "            row = row_dict.copy()\n",
    "            row[column_name]=word\n",
    "            ls.append(row)\n",
    "    return pd.DataFrame(ls)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DFO Description</th>\n",
       "      <th>DFO Description_edit</th>\n",
       "      <th>Important Sentences_edit</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>116 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    DFO Description                               DFO Description_edit  \\\n",
       "0                    HCP does not feel like the data are all that i...   \n",
       "1                    HCP does not feel like the data are all that i...   \n",
       "2                    HCP does not feel like the data are all that i...   \n",
       "3                    HCP does not feel like the data are all that i...   \n",
       "4                    HCP does not feel like the data are all that i...   \n",
       "..              ...                                                ...   \n",
       "111                  HCP does not feel like the data are all that i...   \n",
       "112                  HCP does not feel like the data are all that i...   \n",
       "113                  HCP does not feel like the data are all that i...   \n",
       "114                  HCP does not feel like the data are all that i...   \n",
       "115                  HCP does not feel like the data are all that i...   \n",
       "\n",
       "                    Important Sentences_edit  \n",
       "0    bi-specific data is looking much better  \n",
       "1    bi-specific data is looking much better  \n",
       "2    bi-specific data is looking much better  \n",
       "3    bi-specific data is looking much better  \n",
       "4    bi-specific data is looking much better  \n",
       "..                                       ...  \n",
       "111  bi-specific data is looking much better  \n",
       "112  bi-specific data is looking much better  \n",
       "113  bi-specific data is looking much better  \n",
       "114  bi-specific data is looking much better  \n",
       "115  bi-specific data is looking much better  \n",
       "\n",
       "[116 rows x 3 columns]"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "separate_row(df, \"DFO Description\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tidy_split(df, column, sep='|', keep=False):\n",
    "    \"\"\"\n",
    "    Split the values of a column and expand so the new DataFrame has one split\n",
    "    value per row. Filters rows where the column is missing.\n",
    "\n",
    "    Params\n",
    "    ------\n",
    "    df : pandas.DataFrame\n",
    "        dataframe with the column to split and expand\n",
    "    column : str\n",
    "        the column to split and expand\n",
    "    sep : str\n",
    "        the string used to split the column's values\n",
    "    keep : bool\n",
    "        whether to retain the presplit value as it's own row\n",
    "\n",
    "    Returns\n",
    "    -------\n",
    "    pandas.DataFrame\n",
    "        Returns a dataframe with the same columns as `df`.\n",
    "    \"\"\"\n",
    "    indexes = list()\n",
    "    new_values = list()\n",
    "    df = df.dropna(subset=[column])\n",
    "    for i, presplit in enumerate(df[column].astype(str)):\n",
    "        values = presplit.split(sep)\n",
    "        if keep and len(values) > 1:\n",
    "            indexes.append(i)\n",
    "            new_values.append(presplit)\n",
    "        for value in values:\n",
    "            indexes.append(i)\n",
    "            new_values.append(value)\n",
    "    new_df = df.iloc[indexes, :].copy()\n",
    "    new_df[column] = new_values\n",
    "    return new_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df=  tidy_split(data, column=\"DFO Description\", sep='.', keep=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df['DFO Description']= final_df['DFO Description'].astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df[\"Important Sentences_edit\"]= final_df[\"Important Sentences_edit\"].astype(str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DFO Description</th>\n",
       "      <th>DFO Description_edit</th>\n",
       "      <th>Important Sentences_edit</th>\n",
       "      <th>partial_ratio</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "      <td>HCP does not feel like the data are all that i...</td>\n",
       "      <td>bi-specific data is looking much better</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>HCP feel that giving CART in MM is difficult b...</td>\n",
       "      <td>HCP feel that giving CART in MM is difficult b...</td>\n",
       "      <td>CART in MM is difficult because there are many...</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>He does not feel they are revolutionary like...</td>\n",
       "      <td>HCP feel that giving CART in MM is difficult b...</td>\n",
       "      <td>CART in MM is difficult because there are many...</td>\n",
       "      <td>36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "      <td>HCP feel that giving CART in MM is difficult b...</td>\n",
       "      <td>CART in MM is difficult because there are many...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td>Feels the extra drug may be more toxic and ad...</td>\n",
       "      <td>HCP at large academic center favors a triplet ...</td>\n",
       "      <td>extra drug may be more toxic and adversely aff...</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td></td>\n",
       "      <td>HCP at large academic center favors a triplet ...</td>\n",
       "      <td>extra drug may be more toxic and adversely aff...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>HCP from large academic center stated that whe...</td>\n",
       "      <td>HCP from large academic center stated that whe...</td>\n",
       "      <td>considering recently approved and upcoming the...</td>\n",
       "      <td>100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>Currently prefers CAR T in \"healthier\" younge...</td>\n",
       "      <td>HCP from large academic center stated that whe...</td>\n",
       "      <td>considering recently approved and upcoming the...</td>\n",
       "      <td>33</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td></td>\n",
       "      <td>HCP from large academic center stated that whe...</td>\n",
       "      <td>considering recently approved and upcoming the...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>547 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                       DFO Description  \\\n",
       "0    HCP does not feel like the data are all that i...   \n",
       "0                                                    Â    \n",
       "1    HCP feel that giving CART in MM is difficult b...   \n",
       "1    Â  He does not feel they are revolutionary like...   \n",
       "1                                                   Â Â    \n",
       "..                                                 ...   \n",
       "154   Feels the extra drug may be more toxic and ad...   \n",
       "154                                                      \n",
       "155  HCP from large academic center stated that whe...   \n",
       "155   Currently prefers CAR T in \"healthier\" younge...   \n",
       "155                                                      \n",
       "\n",
       "                                  DFO Description_edit  \\\n",
       "0    HCP does not feel like the data are all that i...   \n",
       "0    HCP does not feel like the data are all that i...   \n",
       "1    HCP feel that giving CART in MM is difficult b...   \n",
       "1    HCP feel that giving CART in MM is difficult b...   \n",
       "1    HCP feel that giving CART in MM is difficult b...   \n",
       "..                                                 ...   \n",
       "154  HCP at large academic center favors a triplet ...   \n",
       "154  HCP at large academic center favors a triplet ...   \n",
       "155  HCP from large academic center stated that whe...   \n",
       "155  HCP from large academic center stated that whe...   \n",
       "155  HCP from large academic center stated that whe...   \n",
       "\n",
       "                              Important Sentences_edit  partial_ratio  \n",
       "0              bi-specific data is looking much better            100  \n",
       "0              bi-specific data is looking much better              0  \n",
       "1    CART in MM is difficult because there are many...            100  \n",
       "1    CART in MM is difficult because there are many...             36  \n",
       "1    CART in MM is difficult because there are many...              0  \n",
       "..                                                 ...            ...  \n",
       "154  extra drug may be more toxic and adversely aff...            100  \n",
       "154  extra drug may be more toxic and adversely aff...              0  \n",
       "155  considering recently approved and upcoming the...            100  \n",
       "155  considering recently approved and upcoming the...             33  \n",
       "155  considering recently approved and upcoming the...              0  \n",
       "\n",
       "[547 rows x 4 columns]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Sumit\\anaconda3\\lib\\site-packages\\fuzzywuzzy\\fuzz.py:11: UserWarning: Using slow pure-python SequenceMatcher. Install python-Levenshtein to remove this warning\n",
      "  warnings.warn('Using slow pure-python SequenceMatcher. Install python-Levenshtein to remove this warning')\n"
     ]
    }
   ],
   "source": [
    "from fuzzywuzzy import fuzz"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df['partial_ratio'] = final_df.apply(lambda x: fuzz.partial_ratio(x['DFO Description'], x['Important Sentences_edit']), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df.to_csv('Final_file.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "lis = final_df['Important Sentences_edit'].to_list()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_list =set(lis)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "142"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(final_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "removing the hemoglobin requirements\n",
      "<class 'str'>\n",
      "dara washout period is going to be a barrier for enrollment\n",
      "<class 'str'>\n",
      "MagnetisMM-5 is a great study\n",
      "<class 'str'>\n",
      "BCMA antibody drug conjugatesÂ are less efficient\n",
      "<class 'str'>\n",
      "often use chemotherapy like bendamustine in their highly refractory MM patients or refer out\n",
      "<class 'str'>\n",
      "more community practices with hematology programs will begin to offer or expand\n",
      "<class 'str'>\n",
      "During study capabilities assessment meeting, HCP states she doesn't usually admit to the hospital for therapy\n",
      "<class 'str'>\n",
      "Targeting BCMA without ocular toxicity and less neurotoxicity\n",
      "<class 'str'>\n",
      "rechallenging a daratumumab-refractory patient with Isatuximab\n",
      "<class 'str'>\n",
      "consider adding anti CD38 in order to hit hard\n",
      "<class 'str'>\n",
      "MRD does not provide much guidance outside of clinical trials\n",
      "<class 'str'>\n",
      "refers all relapse MM patients to primary center\n",
      "<class 'str'>\n",
      "gap in CD38 data is in sequencing and retreatment\n",
      "<class 'str'>\n",
      "more data to prove the interest of those molecules in 2nd or 1st ine\n",
      "<class 'str'>\n",
      "He considers using CART, BCMA and Selinexor single agent.\n",
      "<class 'str'>\n",
      "open up trials allowing novel combinations with prior BCMA\n",
      "<class 'str'>\n",
      "The goal of achieving MRD negativity.Â \n",
      "<class 'str'>\n",
      "caution should be used when sequencing CAR-T and T-cell bispecifics \n",
      "<class 'str'>\n",
      "important to determine the sequence of the treatment targeting BCMA\n",
      "<class 'str'>\n",
      "Daratumumab is prescribed in 1st line. In combination with VRd \n",
      "<class 'str'>\n",
      "priming the patient for a more severe neuropathy AE\n",
      "<class 'str'>\n",
      "waiting to see more QOL data for SQ daratumumab before exploring\n",
      "<class 'str'>\n",
      "Treatment options looking promising to phase out transplant\n",
      "<class 'str'>\n",
      "interested in evaluating a BCMA bi-specific\n",
      "<class 'str'>\n",
      "experience with the compound through clinical trials\n",
      "<class 'str'>\n",
      "FIRST trial is used to determine the treatment\n",
      "<class 'str'>\n",
      "interplay among expression level\n",
      "<class 'str'>\n",
      "The largest barrier to minority recruitment that they have is convincing pharma companies to include community centers\n",
      "<class 'str'>\n",
      "bispecific data were amazing.\n",
      "<class 'str'>\n",
      "Treating these triple refractory patientsÂ is a real challenge\n",
      "<class 'str'>\n",
      "Patients might be review in a pluridisciplinary meeting\n",
      "<class 'str'>\n",
      "frustrated that they are required to repeat training that they previously completed\n",
      "<class 'str'>\n",
      "Tere is a need of QoL data specialy for patient treated in early line.\n",
      "<class 'str'>\n",
      "bi-specific data is looking much better\n",
      "<class 'str'>\n",
      "He is able to admit patients for observation at the community hospital\n",
      "<class 'str'>\n",
      "MM-3 is being highlighted as a trial of interest for BCMA-exposed patients\n",
      "<class 'str'>\n",
      "a patient is refractoryÂ to lenalidomide, the 2 best options are daratumumab/bortezomib/dexamethasone (DVd) and daratumumab/pomalidomide/dexamethasone\n",
      "<class 'str'>\n",
      "Use of tocilizumab was low compared to personal preference\n",
      "<class 'str'>\n",
      "do not have any clinical trials for triple or penta refractory MM\n",
      "<class 'str'>\n",
      "neuropathy seen in 1001 is reversible and how long it lasts\n",
      "<class 'str'>\n",
      "Isa-based regimens due to the need for more supportive care\n",
      "<class 'str'>\n",
      "Daratumumab is used in most of the patients\n",
      "<class 'str'>\n",
      "A new study for the IFM group should use MRD to guide therapeutic decision.\n",
      "<class 'str'>\n",
      "She anticipates good response in the monotherapy arm\n",
      "<class 'str'>\n",
      "triplet (RVD or CyBorD) for transplant-eligible pts\n",
      "<class 'str'>\n",
      "right sequence for patients should be a BCMA Bispecifc, then commercially available Blenrep\n",
      "<class 'str'>\n",
      "HCP at large academic center feels that it will be challenging to recruit Part 2 of MagnetisMM-5.\n",
      "<class 'str'>\n",
      "CART in MM is difficult because there are many hurdles to get a patient to therapy such as good insurance\n",
      "<class 'str'>\n",
      "MM HCP shared her treatment regimen for relapsed MM; which she usually sees during maintenance, she adds DARA, POM or CARF\n",
      "<class 'str'>\n",
      "stop after the 2 years of maintenance many patients will relapse\n",
      "<class 'str'>\n",
      "Using minimal residual disease as a way of deciding which patients can safely afford a treatment holiday\n",
      "<class 'str'>\n",
      "large need for trials in earlier lines\n",
      "<class 'str'>\n",
      "BCMA space is very exciting\n",
      "<class 'str'>\n",
      "CAR-T is not going to be a mainstay therapy in BCMA\n",
      "<class 'str'>\n",
      "Dara-Pom is standard of care in first relapse for the last 5 years\n",
      "<class 'str'>\n",
      "BCMA bispecific antibodies are developed in advanced line of MM\n",
      "<class 'str'>\n",
      "If Elra is better than Dara-Pom-Dex, will take that market\n",
      "<class 'str'>\n",
      "AE events, pre-medication with 20mg dex\n",
      "<class 'str'>\n",
      "CAR T vs bispecific therapies stated that it will be hard for bispecifics to beat Janssen's CAR T\n",
      "<class 'str'>\n",
      "strong bias against hospitalization for treatment.Â  \n",
      "<class 'str'>\n",
      "DRD (based on Maya trial) is best treatment option\n",
      "<class 'str'>\n",
      "Several BCMA bispecific antibodies are in development.\n",
      "<class 'str'>\n",
      "BCMA bispecific therapy in second transplant patients would be straightforward \n",
      "<class 'str'>\n",
      "reassuring that the BCMA directed therapies have higher response rates in MM\n",
      "<class 'str'>\n",
      " high level of interest to see how many CRs or VGPRs convert to deeper responses\n",
      "<class 'str'>\n",
      "Community HCP eager to join in to BCMA trial program\n",
      "<class 'str'>\n",
      "head to head trial would be the only way for this combination maintenance therapy to gain traction\n",
      "<class 'str'>\n",
      "gaps in treatment at the moment\n",
      "<class 'str'>\n",
      " efficacy and safety data looks like before suggesting more trial designs\n",
      "<class 'str'>\n",
      "Ocular toxicity is reversible\n",
      "<class 'str'>\n",
      "CART is very challenging\n",
      "<class 'str'>\n",
      "use of combinations for the management of MM patients, HCP have to adapt the doses all the time\n",
      "<class 'str'>\n",
      "comfortable with using dara as his CD38\n",
      "<class 'str'>\n",
      "BCMA is an attractive additional target\n",
      "<class 'str'>\n",
      " there is significant interest in trying to better define specific risk groups in patients with newly diagnosed MM\n",
      "<class 'str'>\n",
      "there isn't anything special about CD38\n",
      "<class 'str'>\n",
      "generate more data which shows the importance of MRD to determine the choice of treatment\n",
      "<class 'str'>\n",
      "reducing the requirement for a 6 month \"dara holiday\n",
      "<class 'str'>\n",
      "bispecific antibodies are more easy to use, but have to be taken on a long time period\n",
      "<class 'str'>\n",
      "high-risk multiple myeloma and the PFS and OS data from this study will serve as a benchmark for future enrichment design\n",
      "<class 'str'>\n",
      "refer the patient to an academic center\n",
      "<class 'str'>\n",
      "Today MRD is only used in clinical trial.\n",
      "<class 'str'>\n",
      "change in treatment should be initiated\n",
      "<class 'str'>\n",
      " toxicities will be hard for community oncologists to manage.Â \n",
      "<class 'str'>\n",
      "combinatorial strategies with BITES and vaccines\n",
      "<class 'str'>\n",
      "5 day hospitalization is a tough sell for a patient\n",
      "<class 'str'>\n",
      "SQ administration of daratumumab in their practice during COVID pandemic with a great success\n",
      "<class 'str'>\n",
      "heme/ oncs should pay attention\n",
      "<class 'str'>\n",
      "only interested in studies looking at different targets moving forward for their RRMM\n",
      "<class 'str'>\n",
      "they won't have difficulty enrolling 20% African Americans on this study\n",
      "<class 'str'>\n",
      "outside a clinical trial setting, how are you generally approach a younger patient \n",
      "<class 'str'>\n",
      "lower dose of Elranatamab similar to the Blenrep protocol\n",
      "<class 'str'>\n",
      "Belantamab would not be a good choice for a patient who depends on good eyesight\n",
      "<class 'str'>\n",
      "no clinical trial for patients with a creatinine clearance below 30\n",
      "<class 'str'>\n",
      "atients with newly diagnosed high?risk MM receive a 4?drug combination such as daratumumab/bortezomib/lenalidomide/dexamethasone. \n",
      "<class 'str'>\n",
      " The goal is to get into MRD negativity and bring to an auto-SCT.\n",
      "<class 'str'>\n",
      "Daratumumab is an effective treatment which can be taken for years\n",
      "<class 'str'>\n",
      "BCMA CAR-Ts has faded and there is no evidence for a cure in myeloma patients \n",
      "<class 'str'>\n",
      "combination with pomalidomide will be a much better choice\n",
      "<class 'str'>\n",
      "comfortable using this Elranatamab in elderly patients\n",
      "<class 'str'>\n",
      "MRD is not standard of care yet\n",
      "<class 'str'>\n",
      "o standard of treatment of triple class refractory MM patients. The choice of treatment will depend on patient charactÃ©ristic\n",
      "<class 'str'>\n",
      "CART therapy is not producing great DOR\n",
      "<class 'str'>\n",
      "Before to proceed to ASCT, there is an assessment of the cardiac, renal fonction, comorbidities\n",
      "<class 'str'>\n",
      "HCP will mostly introduce daratumumab in the second line setting \n",
      "<class 'str'>\n",
      "interesting to investigate whether the immune system might influence the response to BCMA bispecific antiboies.\n",
      "<class 'str'>\n",
      "interest in post HSCT maintenance studies in MM\n",
      "<class 'str'>\n",
      "differentiate Bispecifics from CAR-T will be when response durability after 12 months\n",
      "<class 'str'>\n",
      "move these trials into earlier lines of therapy or post HSCT\n",
      "<class 'str'>\n",
      "States continued excitement about trial and expresses hope for it will be available for the patients \n",
      "<class 'str'>\n",
      "extra drug may be more toxic and adversely affect transplant\n",
      "<class 'str'>\n",
      "only used blenrep once.Â  Their center does not have good overlap with an ophthalmologist\n",
      "<class 'str'>\n",
      "Prefers to use quadruplet therapy (adding an anti-CD38) or for more frail patients usually uses Dara/Len/Dex\n",
      "<class 'str'>\n",
      "Site does not want to use SIP at all\n",
      "<class 'str'>\n",
      "required to call 3rd party vendors to get them to transfer it\n",
      "<class 'str'>\n",
      "treat CRS by using Tylenol for fever and tocilizumab in patients\n",
      "<class 'str'>\n",
      "CRS data is not a problem\n",
      "<class 'str'>\n",
      "people with lower incomes (regardless of race) had lower trial participation\n",
      "<class 'str'>\n",
      "(KRd), but she keeps cardiovascular risks in mind\n",
      "<class 'str'>\n",
      "Pfizer should be able to assign training\n",
      "<class 'str'>\n",
      "if the patient has renal issues, he gives DARA/POM/dex.Â Â \n",
      "<class 'str'>\n",
      "Neurotoxicity has not been a significant issue in any of these MM CARÂ T-cell trials, \n",
      "<class 'str'>\n",
      "BCMA is a crucial target to advance\n",
      "<class 'str'>\n",
      "considering recently approved and upcoming therapies, needs to see all data\n",
      "<class 'str'>\n",
      "SelinexorÂ  seems to be a excellent drug if given over time\n",
      "<class 'str'>\n",
      "If there was a washout, he'd use a BCMA therapy or clinical trial to bridge.Â  \n",
      "<class 'str'>\n",
      "patients could start with dara-VRD then do a non-dara regimen next then back to a dara regimen.\n",
      "<class 'str'>\n",
      "prefer to treat younger, sicker patients with a bispecific rather than CAR T\n",
      "<class 'str'>\n",
      "Bispecifics will be used more frequently due to the limited scalability with CAR T.\n",
      "<class 'str'>\n",
      "put them on a trial if they have one for the patient\n",
      "<class 'str'>\n",
      "using dara in the third line of therapy because it typically works when patients aren't responding to other agents\n",
      "<class 'str'>\n",
      "transgene (2 CARs) mechanism that binds BCMA in different spots\n",
      "<class 'str'>\n",
      "delay 3-4 cycles using a higher dose\n",
      "<class 'str'>\n",
      "Largest barrier of including minorities in trials and getting them equal treatment opportunity for MM is the rural/urban dichotomy.\n",
      "<class 'str'>\n",
      "nan\n",
      "<class 'str'>\n",
      "would like BCMA trials for consolidation in pts\n",
      "<class 'str'>\n",
      "Challenging to recruit Part 2 of MagnetisMM-5\n",
      "<class 'str'>\n",
      "restricted I/E criteria\n",
      "<class 'str'>\n",
      "HCP expressed that enrollment in MM-5 will be difficult\n",
      "<class 'str'>\n",
      "much higher incidence of opportunistic infections due to neutropaenia\n",
      "<class 'str'>\n",
      "it?s extremely reassuring and refreshing to see validation of new immunotherapy targets for treating MM\n",
      "<class 'str'>\n",
      "HCP states he heard about the hold on the elranatamab program\n",
      "<class 'str'>\n"
     ]
    }
   ],
   "source": [
    "for i in final_list:\n",
    "    print(i)\n",
    "    print(type(i))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "def unique(list1):\n",
    "    x = np.array(list1)\n",
    "    print(np.unique(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[' The goal is to get into MRD negativity and bring to an auto-SCT.'\n",
      " ' efficacy and safety data looks like before suggesting more trial designs'\n",
      " ' high level of interest to see how many CRs or VGPRs convert to deeper responses'\n",
      " ' there is significant interest in trying to better define specific risk groups in patients with newly diagnosed MM'\n",
      " ' toxicities will be hard for community oncologists to manage.\\xa0'\n",
      " '(KRd), but she keeps cardiovascular risks in mind'\n",
      " '5 day hospitalization is a tough sell for a patient'\n",
      " 'A new study for the IFM group should use MRD to guide therapeutic decision.'\n",
      " 'AE events, pre-medication with 20mg dex'\n",
      " 'BCMA CAR-Ts has faded and there is no evidence for a cure in myeloma patients '\n",
      " 'BCMA antibody drug conjugates\\xa0are less efficient'\n",
      " 'BCMA bispecific antibodies are developed in advanced line of MM'\n",
      " 'BCMA bispecific therapy in second transplant patients would be straightforward '\n",
      " 'BCMA is a crucial target to advance'\n",
      " 'BCMA is an attractive additional target' 'BCMA space is very exciting'\n",
      " 'Before to proceed to ASCT, there is an assessment of the cardiac, renal fonction, comorbidities'\n",
      " 'Belantamab would not be a good choice for a patient who depends on good eyesight'\n",
      " 'Bispecifics will be used more frequently due to the limited scalability with CAR T.'\n",
      " \"CAR T vs bispecific therapies stated that it will be hard for bispecifics to beat Janssen's CAR T\"\n",
      " 'CAR-T is not going to be a mainstay therapy in BCMA'\n",
      " 'CART in MM is difficult because there are many hurdles to get a patient to therapy such as good insurance'\n",
      " 'CART is very challenging' 'CART therapy is not producing great DOR'\n",
      " 'CRS data is not a problem'\n",
      " 'Challenging to recruit Part 2 of MagnetisMM-5'\n",
      " 'Community HCP eager to join in to BCMA trial program'\n",
      " 'DRD (based on Maya trial) is best treatment option'\n",
      " 'Dara-Pom is standard of care in first relapse for the last 5 years'\n",
      " 'Daratumumab is an effective treatment which can be taken for years'\n",
      " 'Daratumumab is prescribed in 1st line. In combination with VRd '\n",
      " 'Daratumumab is used in most of the patients'\n",
      " \"During study capabilities assessment meeting, HCP states she doesn't usually admit to the hospital for therapy\"\n",
      " 'FIRST trial is used to determine the treatment'\n",
      " 'HCP at large academic center feels that it will be challenging to recruit Part 2 of MagnetisMM-5.'\n",
      " 'HCP expressed that enrollment in MM-5 will be difficult'\n",
      " 'HCP states he heard about the hold on the elranatamab program'\n",
      " 'HCP will mostly introduce daratumumab in the second line setting '\n",
      " 'He considers using CART, BCMA and Selinexor single agent.'\n",
      " 'He is able to admit patients for observation at the community hospital'\n",
      " 'If Elra is better than Dara-Pom-Dex, will take that market'\n",
      " \"If there was a washout, he'd use a BCMA therapy or clinical trial to bridge.\\xa0 \"\n",
      " 'Isa-based regimens due to the need for more supportive care'\n",
      " 'Largest barrier of including minorities in trials and getting them equal treatment opportunity for MM is the rural/urban dichotomy.'\n",
      " 'MM HCP shared her treatment regimen for relapsed MM; which she usually sees during maintenance, she adds DARA, POM or CARF'\n",
      " 'MM-3 is being highlighted as a trial of interest for BCMA-exposed patients'\n",
      " 'MRD does not provide much guidance outside of clinical trials'\n",
      " 'MRD is not standard of care yet' 'MagnetisMM-5 is a great study'\n",
      " 'Neurotoxicity has not been a significant issue in any of these MM CAR\\xa0T-cell trials, '\n",
      " 'Ocular toxicity is reversible'\n",
      " 'Patients might be review in a pluridisciplinary meeting'\n",
      " 'Pfizer should be able to assign training'\n",
      " 'Prefers to use quadruplet therapy (adding an anti-CD38) or for more frail patients usually uses Dara/Len/Dex'\n",
      " 'SQ administration of daratumumab in their practice during COVID pandemic with a great success'\n",
      " 'Selinexor\\xa0 seems to be a excellent drug if given over time'\n",
      " 'Several BCMA bispecific antibodies are in development.'\n",
      " 'She anticipates good response in the monotherapy arm'\n",
      " 'Site does not want to use SIP at all'\n",
      " 'States continued excitement about trial and expresses hope for it will be available for the patients '\n",
      " 'Targeting BCMA without ocular toxicity and less neurotoxicity'\n",
      " 'Tere is a need of QoL data specialy for patient treated in early line.'\n",
      " 'The goal of achieving MRD negativity.\\xa0'\n",
      " 'The largest barrier to minority recruitment that they have is convincing pharma companies to include community centers'\n",
      " 'Today MRD is only used in clinical trial.'\n",
      " 'Treating these triple refractory patients\\xa0is a real challenge'\n",
      " 'Treatment options looking promising to phase out transplant'\n",
      " 'Use of tocilizumab was low compared to personal preference'\n",
      " 'Using minimal residual disease as a way of deciding which patients can safely afford a treatment holiday'\n",
      " 'a patient is refractory\\xa0to lenalidomide, the 2 best options are daratumumab/bortezomib/dexamethasone (DVd) and daratumumab/pomalidomide/dexamethasone'\n",
      " 'atients with newly diagnosed high?risk MM receive a 4?drug combination such as daratumumab/bortezomib/lenalidomide/dexamethasone. '\n",
      " 'bi-specific data is looking much better'\n",
      " 'bispecific antibodies are more easy to use, but have to be taken on a long time period'\n",
      " 'bispecific data were amazing.'\n",
      " 'caution should be used when sequencing CAR-T and T-cell bispecifics '\n",
      " 'change in treatment should be initiated'\n",
      " 'combination with pomalidomide will be a much better choice'\n",
      " 'combinatorial strategies with BITES and vaccines'\n",
      " 'comfortable using this Elranatamab in elderly patients'\n",
      " 'comfortable with using dara as his CD38'\n",
      " 'consider adding anti CD38 in order to hit hard'\n",
      " 'considering recently approved and upcoming therapies, needs to see all data'\n",
      " 'dara washout period is going to be a barrier for enrollment'\n",
      " 'delay 3-4 cycles using a higher dose'\n",
      " 'differentiate Bispecifics from CAR-T will be when response durability after 12 months'\n",
      " 'do not have any clinical trials for triple or penta refractory MM'\n",
      " 'experience with the compound through clinical trials'\n",
      " 'extra drug may be more toxic and adversely affect transplant'\n",
      " 'frustrated that they are required to repeat training that they previously completed'\n",
      " 'gap in CD38 data is in sequencing and retreatment'\n",
      " 'gaps in treatment at the moment'\n",
      " 'generate more data which shows the importance of MRD to determine the choice of treatment'\n",
      " 'head to head trial would be the only way for this combination maintenance therapy to gain traction'\n",
      " 'heme/ oncs should pay attention'\n",
      " 'high-risk multiple myeloma and the PFS and OS data from this study will serve as a benchmark for future enrichment design'\n",
      " 'if the patient has renal issues, he gives DARA/POM/dex.\\xa0\\xa0'\n",
      " 'important to determine the sequence of the treatment targeting BCMA'\n",
      " 'interest in post HSCT maintenance studies in MM'\n",
      " 'interested in evaluating a BCMA bi-specific'\n",
      " 'interesting to investigate whether the immune system might influence the response to BCMA bispecific antiboies.'\n",
      " 'interplay among expression level'\n",
      " 'it?s extremely reassuring and refreshing to see validation of new immunotherapy targets for treating MM'\n",
      " 'large need for trials in earlier lines'\n",
      " 'lower dose of Elranatamab similar to the Blenrep protocol'\n",
      " 'more community practices with hematology programs will begin to offer or expand'\n",
      " 'more data to prove the interest of those molecules in 2nd or 1st ine'\n",
      " 'move these trials into earlier lines of therapy or post HSCT'\n",
      " 'much higher incidence of opportunistic infections due to neutropaenia'\n",
      " 'nan' 'neuropathy seen in 1001 is reversible and how long it lasts'\n",
      " 'no clinical trial for patients with a creatinine clearance below 30'\n",
      " 'o standard of treatment of triple class refractory MM patients. The choice of treatment will depend on patient charactÃ©ristic'\n",
      " 'often use chemotherapy like bendamustine in their highly refractory MM patients or refer out'\n",
      " 'only interested in studies looking at different targets moving forward for their RRMM'\n",
      " 'only used blenrep once.\\xa0 Their center does not have good overlap with an ophthalmologist'\n",
      " 'open up trials allowing novel combinations with prior BCMA'\n",
      " 'outside a clinical trial setting, how are you generally approach a younger patient '\n",
      " 'patients could start with dara-VRD then do a non-dara regimen next then back to a dara regimen.'\n",
      " 'people with lower incomes (regardless of race) had lower trial participation'\n",
      " 'prefer to treat younger, sicker patients with a bispecific rather than CAR T'\n",
      " 'priming the patient for a more severe neuropathy AE'\n",
      " 'put them on a trial if they have one for the patient'\n",
      " 'reassuring that the BCMA directed therapies have higher response rates in MM'\n",
      " 'rechallenging a daratumumab-refractory patient with Isatuximab'\n",
      " 'reducing the requirement for a 6 month \"dara holiday'\n",
      " 'refer the patient to an academic center'\n",
      " 'refers all relapse MM patients to primary center'\n",
      " 'removing the hemoglobin requirements'\n",
      " 'required to call 3rd party vendors to get them to transfer it'\n",
      " 'restricted I/E criteria'\n",
      " 'right sequence for patients should be a BCMA Bispecifc, then commercially available Blenrep'\n",
      " 'stop after the 2 years of maintenance many patients will relapse'\n",
      " 'strong bias against hospitalization for treatment.\\xa0 '\n",
      " \"there isn't anything special about CD38\"\n",
      " \"they won't have difficulty enrolling 20% African Americans on this study\"\n",
      " 'transgene (2 CARs) mechanism that binds BCMA in different spots'\n",
      " 'treat CRS by using Tylenol for fever and tocilizumab in patients'\n",
      " 'triplet (RVD or CyBorD) for transplant-eligible pts'\n",
      " 'use of combinations for the management of MM patients, HCP have to adapt the doses all the time'\n",
      " \"using dara in the third line of therapy because it typically works when patients aren't responding to other agents\"\n",
      " 'waiting to see more QOL data for SQ daratumumab before exploring'\n",
      " 'would like BCMA trials for consolidation in pts']\n"
     ]
    }
   ],
   "source": [
    "final_lis = unique(lis)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "547"
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(lis)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "142"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(final_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_similarity_score(dfo, imp_sentence_list): \n",
    "    #my_lis =[]\n",
    "    for i in imp_sentence_list:\n",
    "        x = fuzz.partial_ratio(dfo, i)\n",
    "        if x>80: \n",
    "            print(x)\n",
    "    return x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "imp_sen1\n",
    "\n",
    "import numpy as np\n",
    "\n",
    "#mylist = [3, 4, 5, np.nan]\n",
    "l = [x for x in imp_sen1 if pd.notnull(x)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['prefer to treat younger, sicker patients with a bispecific rather than CAR T',\n",
       " 'o standard of treatment of triple class refractory MM patients. The choice of treatment will depend on patient charactÃ©ristic',\n",
       " 'Use of tocilizumab was low compared to personal preference',\n",
       " 'MagnetisMM-5 is a great study',\n",
       " ' high level of interest to see how many CRs or VGPRs convert to deeper responses',\n",
       " 'required to call 3rd party vendors to get them to transfer it',\n",
       " 'SQ administration of daratumumab in their practice during COVID pandemic with a great success',\n",
       " 'bispecific antibodies are more easy to use, but have to be taken on a long time period',\n",
       " '5 day hospitalization is a tough sell for a patient',\n",
       " 'BCMA antibody drug conjugates\\xa0are less efficient',\n",
       " 'Challenging to recruit Part 2 of MagnetisMM-5',\n",
       " 'delay 3-4 cycles using a higher dose',\n",
       " 'CART therapy is not producing great DOR',\n",
       " 'comfortable using this Elranatamab in elderly patients',\n",
       " 'Pfizer should be able to assign training',\n",
       " 'Bispecifics will be used more frequently due to the limited scalability with CAR T.',\n",
       " 'lower dose of Elranatamab similar to the Blenrep protocol',\n",
       " 'refer the patient to an academic center',\n",
       " 'Dara-Pom is standard of care in first relapse for the last 5 years',\n",
       " 'BCMA is a crucial target to advance',\n",
       " 'extra drug may be more toxic and adversely affect transplant',\n",
       " 'consider adding anti CD38 in order to hit hard',\n",
       " 'combinatorial strategies with BITES and vaccines',\n",
       " 'comfortable with using dara as his CD38',\n",
       " 'interested in evaluating a BCMA bi-specific',\n",
       " ' there is significant interest in trying to better define specific risk groups in patients with newly diagnosed MM',\n",
       " 'people with lower incomes (regardless of race) had lower trial participation',\n",
       " 'Prefers to use quadruplet therapy (adding an anti-CD38) or for more frail patients usually uses Dara/Len/Dex',\n",
       " 'removing the hemoglobin requirements',\n",
       " \"During study capabilities assessment meeting, HCP states she doesn't usually admit to the hospital for therapy\",\n",
       " 'Daratumumab is an effective treatment which can be taken for years',\n",
       " 'strong bias against hospitalization for treatment.\\xa0 ',\n",
       " 'outside a clinical trial setting, how are you generally approach a younger patient ',\n",
       " 'HCP will mostly introduce daratumumab in the second line setting ',\n",
       " '(KRd), but she keeps cardiovascular risks in mind',\n",
       " 'MRD is not standard of care yet',\n",
       " 'only interested in studies looking at different targets moving forward for their RRMM',\n",
       " 'patients could start with dara-VRD then do a non-dara regimen next then back to a dara regimen.',\n",
       " 'Daratumumab is used in most of the patients',\n",
       " 'Ocular toxicity is reversible',\n",
       " 'a patient is refractory\\xa0to lenalidomide, the 2 best options are daratumumab/bortezomib/dexamethasone (DVd) and daratumumab/pomalidomide/dexamethasone',\n",
       " 'stop after the 2 years of maintenance many patients will relapse',\n",
       " 'MRD does not provide much guidance outside of clinical trials',\n",
       " 'Belantamab would not be a good choice for a patient who depends on good eyesight',\n",
       " 'high-risk multiple myeloma and the PFS and OS data from this study will serve as a benchmark for future enrichment design',\n",
       " 'experience with the compound through clinical trials',\n",
       " \"there isn't anything special about CD38\",\n",
       " 'If Elra is better than Dara-Pom-Dex, will take that market',\n",
       " 'head to head trial would be the only way for this combination maintenance therapy to gain traction',\n",
       " 'dara washout period is going to be a barrier for enrollment',\n",
       " \"using dara in the third line of therapy because it typically works when patients aren't responding to other agents\",\n",
       " 'Several BCMA bispecific antibodies are in development.',\n",
       " 'neuropathy seen in 1001 is reversible and how long it lasts',\n",
       " 'gaps in treatment at the moment',\n",
       " 'atients with newly diagnosed high?risk MM receive a 4?drug combination such as daratumumab/bortezomib/lenalidomide/dexamethasone. ',\n",
       " 'HCP expressed that enrollment in MM-5 will be difficult',\n",
       " 'interplay among expression level',\n",
       " 'Treatment options looking promising to phase out transplant',\n",
       " 'States continued excitement about trial and expresses hope for it will be available for the patients ',\n",
       " 'more community practices with hematology programs will begin to offer or expand',\n",
       " 'The goal of achieving MRD negativity.\\xa0',\n",
       " 'treat CRS by using Tylenol for fever and tocilizumab in patients',\n",
       " 'Selinexor\\xa0 seems to be a excellent drug if given over time',\n",
       " 'restricted I/E criteria',\n",
       " 'move these trials into earlier lines of therapy or post HSCT',\n",
       " 'change in treatment should be initiated',\n",
       " 'no clinical trial for patients with a creatinine clearance below 30',\n",
       " 'He considers using CART, BCMA and Selinexor single agent.',\n",
       " 'differentiate Bispecifics from CAR-T will be when response durability after 12 months',\n",
       " 'much higher incidence of opportunistic infections due to neutropaenia',\n",
       " 'use of combinations for the management of MM patients, HCP have to adapt the doses all the time',\n",
       " \"CAR T vs bispecific therapies stated that it will be hard for bispecifics to beat Janssen's CAR T\",\n",
       " ' toxicities will be hard for community oncologists to manage.\\xa0',\n",
       " 'interest in post HSCT maintenance studies in MM',\n",
       " 'A new study for the IFM group should use MRD to guide therapeutic decision.',\n",
       " 'Treating these triple refractory patients\\xa0is a real challenge',\n",
       " 'CART is very challenging',\n",
       " 'BCMA space is very exciting',\n",
       " 'BCMA CAR-Ts has faded and there is no evidence for a cure in myeloma patients ',\n",
       " 'HCP states he heard about the hold on the elranatamab program',\n",
       " 'right sequence for patients should be a BCMA Bispecifc, then commercially available Blenrep',\n",
       " 'reassuring that the BCMA directed therapies have higher response rates in MM',\n",
       " 'He is able to admit patients for observation at the community hospital',\n",
       " 'put them on a trial if they have one for the patient',\n",
       " 'Community HCP eager to join in to BCMA trial program',\n",
       " 'BCMA bispecific antibodies are developed in advanced line of MM',\n",
       " 'MM HCP shared her treatment regimen for relapsed MM; which she usually sees during maintenance, she adds DARA, POM or CARF',\n",
       " 'CRS data is not a problem',\n",
       " 'interesting to investigate whether the immune system might influence the response to BCMA bispecific antiboies.',\n",
       " 'Patients might be review in a pluridisciplinary meeting',\n",
       " 'gap in CD38 data is in sequencing and retreatment',\n",
       " 'open up trials allowing novel combinations with prior BCMA',\n",
       " 'Site does not want to use SIP at all',\n",
       " 'The largest barrier to minority recruitment that they have is convincing pharma companies to include community centers',\n",
       " 'AE events, pre-medication with 20mg dex',\n",
       " 'BCMA is an attractive additional target',\n",
       " 'only used blenrep once.\\xa0 Their center does not have good overlap with an ophthalmologist',\n",
       " 'Today MRD is only used in clinical trial.',\n",
       " 'bispecific data were amazing.',\n",
       " ' The goal is to get into MRD negativity and bring to an auto-SCT.',\n",
       " 'HCP at large academic center feels that it will be challenging to recruit Part 2 of MagnetisMM-5.',\n",
       " \"they won't have difficulty enrolling 20% African Americans on this study\",\n",
       " 'bi-specific data is looking much better',\n",
       " 'often use chemotherapy like bendamustine in their highly refractory MM patients or refer out',\n",
       " 'Before to proceed to ASCT, there is an assessment of the cardiac, renal fonction, comorbidities',\n",
       " 'Neurotoxicity has not been a significant issue in any of these MM CAR\\xa0T-cell trials, ',\n",
       " 'do not have any clinical trials for triple or penta refractory MM',\n",
       " 'CAR-T is not going to be a mainstay therapy in BCMA',\n",
       " 'it?s extremely reassuring and refreshing to see validation of new immunotherapy targets for treating MM',\n",
       " 'She anticipates good response in the monotherapy arm',\n",
       " 'caution should be used when sequencing CAR-T and T-cell bispecifics ',\n",
       " 'Tere is a need of QoL data specialy for patient treated in early line.',\n",
       " 'combination with pomalidomide will be a much better choice',\n",
       " 'would like BCMA trials for consolidation in pts',\n",
       " 'Using minimal residual disease as a way of deciding which patients can safely afford a treatment holiday',\n",
       " 'CART in MM is difficult because there are many hurdles to get a patient to therapy such as good insurance',\n",
       " 'FIRST trial is used to determine the treatment',\n",
       " 'considering recently approved and upcoming therapies, needs to see all data',\n",
       " 'MM-3 is being highlighted as a trial of interest for BCMA-exposed patients',\n",
       " ' efficacy and safety data looks like before suggesting more trial designs',\n",
       " \"If there was a washout, he'd use a BCMA therapy or clinical trial to bridge.\\xa0 \",\n",
       " 'important to determine the sequence of the treatment targeting BCMA',\n",
       " 'Daratumumab is prescribed in 1st line. In combination with VRd ',\n",
       " 'generate more data which shows the importance of MRD to determine the choice of treatment',\n",
       " 'frustrated that they are required to repeat training that they previously completed',\n",
       " 'DRD (based on Maya trial) is best treatment option',\n",
       " 'Targeting BCMA without ocular toxicity and less neurotoxicity',\n",
       " 'Largest barrier of including minorities in trials and getting them equal treatment opportunity for MM is the rural/urban dichotomy.',\n",
       " 'if the patient has renal issues, he gives DARA/POM/dex.\\xa0\\xa0',\n",
       " 'transgene (2 CARs) mechanism that binds BCMA in different spots',\n",
       " 'large need for trials in earlier lines',\n",
       " 'Isa-based regimens due to the need for more supportive care',\n",
       " 'waiting to see more QOL data for SQ daratumumab before exploring',\n",
       " 'priming the patient for a more severe neuropathy AE',\n",
       " 'BCMA bispecific therapy in second transplant patients would be straightforward ',\n",
       " 'rechallenging a daratumumab-refractory patient with Isatuximab',\n",
       " 'reducing the requirement for a 6 month \"dara holiday',\n",
       " 'refers all relapse MM patients to primary center',\n",
       " 'triplet (RVD or CyBorD) for transplant-eligible pts',\n",
       " 'more data to prove the interest of those molecules in 2nd or 1st ine',\n",
       " 'heme/ oncs should pay attention']"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "l"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'str'>\n",
      "prefer to treat younger, sicker patients with a bispecific rather than CAR T\n",
      "<class 'str'>\n",
      "o standard of treatment of triple class refractory MM patients. The choice of treatment will depend on patient charactÃ©ristic\n",
      "<class 'str'>\n",
      "Use of tocilizumab was low compared to personal preference\n",
      "<class 'str'>\n",
      "MagnetisMM-5 is a great study\n",
      "<class 'str'>\n",
      " high level of interest to see how many CRs or VGPRs convert to deeper responses\n",
      "<class 'str'>\n",
      "required to call 3rd party vendors to get them to transfer it\n",
      "<class 'str'>\n",
      "SQ administration of daratumumab in their practice during COVID pandemic with a great success\n",
      "<class 'str'>\n",
      "bispecific antibodies are more easy to use, but have to be taken on a long time period\n",
      "<class 'str'>\n",
      "5 day hospitalization is a tough sell for a patient\n",
      "<class 'str'>\n",
      "BCMA antibody drug conjugatesÂ are less efficient\n",
      "<class 'str'>\n",
      "Challenging to recruit Part 2 of MagnetisMM-5\n",
      "<class 'str'>\n",
      "delay 3-4 cycles using a higher dose\n",
      "<class 'str'>\n",
      "CART therapy is not producing great DOR\n",
      "<class 'str'>\n",
      "comfortable using this Elranatamab in elderly patients\n",
      "<class 'str'>\n",
      "Pfizer should be able to assign training\n",
      "<class 'str'>\n",
      "Bispecifics will be used more frequently due to the limited scalability with CAR T.\n",
      "<class 'str'>\n",
      "lower dose of Elranatamab similar to the Blenrep protocol\n",
      "<class 'str'>\n",
      "refer the patient to an academic center\n",
      "<class 'str'>\n",
      "Dara-Pom is standard of care in first relapse for the last 5 years\n",
      "<class 'str'>\n",
      "BCMA is a crucial target to advance\n",
      "<class 'str'>\n",
      "extra drug may be more toxic and adversely affect transplant\n",
      "<class 'str'>\n",
      "consider adding anti CD38 in order to hit hard\n",
      "<class 'str'>\n",
      "combinatorial strategies with BITES and vaccines\n",
      "<class 'str'>\n",
      "comfortable with using dara as his CD38\n",
      "<class 'str'>\n",
      "interested in evaluating a BCMA bi-specific\n",
      "<class 'str'>\n",
      " there is significant interest in trying to better define specific risk groups in patients with newly diagnosed MM\n",
      "<class 'str'>\n",
      "people with lower incomes (regardless of race) had lower trial participation\n",
      "<class 'str'>\n",
      "Prefers to use quadruplet therapy (adding an anti-CD38) or for more frail patients usually uses Dara/Len/Dex\n",
      "<class 'str'>\n",
      "removing the hemoglobin requirements\n",
      "<class 'str'>\n",
      "During study capabilities assessment meeting, HCP states she doesn't usually admit to the hospital for therapy\n",
      "<class 'str'>\n",
      "Daratumumab is an effective treatment which can be taken for years\n",
      "<class 'str'>\n",
      "strong bias against hospitalization for treatment.Â  \n",
      "<class 'str'>\n",
      "outside a clinical trial setting, how are you generally approach a younger patient \n",
      "<class 'str'>\n",
      "HCP will mostly introduce daratumumab in the second line setting \n",
      "<class 'str'>\n",
      "(KRd), but she keeps cardiovascular risks in mind\n",
      "<class 'str'>\n",
      "MRD is not standard of care yet\n",
      "<class 'str'>\n",
      "only interested in studies looking at different targets moving forward for their RRMM\n",
      "<class 'str'>\n",
      "patients could start with dara-VRD then do a non-dara regimen next then back to a dara regimen.\n",
      "<class 'str'>\n",
      "Daratumumab is used in most of the patients\n",
      "<class 'str'>\n",
      "Ocular toxicity is reversible\n",
      "<class 'str'>\n",
      "a patient is refractoryÂ to lenalidomide, the 2 best options are daratumumab/bortezomib/dexamethasone (DVd) and daratumumab/pomalidomide/dexamethasone\n",
      "<class 'str'>\n",
      "stop after the 2 years of maintenance many patients will relapse\n",
      "<class 'str'>\n",
      "MRD does not provide much guidance outside of clinical trials\n",
      "<class 'str'>\n",
      "Belantamab would not be a good choice for a patient who depends on good eyesight\n",
      "<class 'str'>\n",
      "high-risk multiple myeloma and the PFS and OS data from this study will serve as a benchmark for future enrichment design\n",
      "<class 'str'>\n",
      "experience with the compound through clinical trials\n",
      "<class 'str'>\n",
      "there isn't anything special about CD38\n",
      "<class 'str'>\n",
      "If Elra is better than Dara-Pom-Dex, will take that market\n",
      "<class 'str'>\n",
      "head to head trial would be the only way for this combination maintenance therapy to gain traction\n",
      "<class 'str'>\n",
      "dara washout period is going to be a barrier for enrollment\n",
      "<class 'str'>\n",
      "using dara in the third line of therapy because it typically works when patients aren't responding to other agents\n",
      "<class 'str'>\n",
      "Several BCMA bispecific antibodies are in development.\n",
      "<class 'str'>\n",
      "neuropathy seen in 1001 is reversible and how long it lasts\n",
      "<class 'str'>\n",
      "gaps in treatment at the moment\n",
      "<class 'str'>\n",
      "atients with newly diagnosed high?risk MM receive a 4?drug combination such as daratumumab/bortezomib/lenalidomide/dexamethasone. \n",
      "<class 'str'>\n",
      "HCP expressed that enrollment in MM-5 will be difficult\n",
      "<class 'str'>\n",
      "interplay among expression level\n",
      "<class 'str'>\n",
      "Treatment options looking promising to phase out transplant\n",
      "<class 'str'>\n",
      "States continued excitement about trial and expresses hope for it will be available for the patients \n",
      "<class 'str'>\n",
      "more community practices with hematology programs will begin to offer or expand\n",
      "<class 'str'>\n",
      "The goal of achieving MRD negativity.Â \n",
      "<class 'str'>\n",
      "treat CRS by using Tylenol for fever and tocilizumab in patients\n",
      "<class 'str'>\n",
      "SelinexorÂ  seems to be a excellent drug if given over time\n",
      "<class 'str'>\n",
      "restricted I/E criteria\n",
      "<class 'str'>\n",
      "move these trials into earlier lines of therapy or post HSCT\n",
      "<class 'str'>\n",
      "change in treatment should be initiated\n",
      "<class 'str'>\n",
      "no clinical trial for patients with a creatinine clearance below 30\n",
      "<class 'str'>\n",
      "He considers using CART, BCMA and Selinexor single agent.\n",
      "<class 'str'>\n",
      "differentiate Bispecifics from CAR-T will be when response durability after 12 months\n",
      "<class 'str'>\n",
      "much higher incidence of opportunistic infections due to neutropaenia\n",
      "<class 'str'>\n",
      "use of combinations for the management of MM patients, HCP have to adapt the doses all the time\n",
      "<class 'str'>\n",
      "CAR T vs bispecific therapies stated that it will be hard for bispecifics to beat Janssen's CAR T\n",
      "<class 'str'>\n",
      " toxicities will be hard for community oncologists to manage.Â \n",
      "<class 'str'>\n",
      "interest in post HSCT maintenance studies in MM\n",
      "<class 'str'>\n",
      "A new study for the IFM group should use MRD to guide therapeutic decision.\n",
      "<class 'str'>\n",
      "Treating these triple refractory patientsÂ is a real challenge\n",
      "<class 'str'>\n",
      "CART is very challenging\n",
      "<class 'str'>\n",
      "BCMA space is very exciting\n",
      "<class 'str'>\n",
      "BCMA CAR-Ts has faded and there is no evidence for a cure in myeloma patients \n",
      "<class 'str'>\n",
      "HCP states he heard about the hold on the elranatamab program\n",
      "<class 'str'>\n",
      "right sequence for patients should be a BCMA Bispecifc, then commercially available Blenrep\n",
      "<class 'str'>\n",
      "reassuring that the BCMA directed therapies have higher response rates in MM\n",
      "<class 'str'>\n",
      "He is able to admit patients for observation at the community hospital\n",
      "<class 'str'>\n",
      "put them on a trial if they have one for the patient\n",
      "<class 'str'>\n",
      "Community HCP eager to join in to BCMA trial program\n",
      "<class 'str'>\n",
      "BCMA bispecific antibodies are developed in advanced line of MM\n",
      "<class 'str'>\n",
      "MM HCP shared her treatment regimen for relapsed MM; which she usually sees during maintenance, she adds DARA, POM or CARF\n",
      "<class 'str'>\n",
      "CRS data is not a problem\n",
      "<class 'str'>\n",
      "interesting to investigate whether the immune system might influence the response to BCMA bispecific antiboies.\n",
      "<class 'str'>\n",
      "Patients might be review in a pluridisciplinary meeting\n",
      "<class 'str'>\n",
      "gap in CD38 data is in sequencing and retreatment\n",
      "<class 'str'>\n",
      "open up trials allowing novel combinations with prior BCMA\n",
      "<class 'str'>\n",
      "Site does not want to use SIP at all\n",
      "<class 'str'>\n",
      "The largest barrier to minority recruitment that they have is convincing pharma companies to include community centers\n",
      "<class 'str'>\n",
      "AE events, pre-medication with 20mg dex\n",
      "<class 'str'>\n",
      "BCMA is an attractive additional target\n",
      "<class 'str'>\n",
      "only used blenrep once.Â  Their center does not have good overlap with an ophthalmologist\n",
      "<class 'str'>\n",
      "Today MRD is only used in clinical trial.\n",
      "<class 'str'>\n",
      "bispecific data were amazing.\n",
      "<class 'str'>\n",
      " The goal is to get into MRD negativity and bring to an auto-SCT.\n",
      "<class 'str'>\n",
      "HCP at large academic center feels that it will be challenging to recruit Part 2 of MagnetisMM-5.\n",
      "<class 'str'>\n",
      "they won't have difficulty enrolling 20% African Americans on this study\n",
      "<class 'str'>\n",
      "bi-specific data is looking much better\n",
      "<class 'str'>\n",
      "often use chemotherapy like bendamustine in their highly refractory MM patients or refer out\n",
      "<class 'str'>\n",
      "Before to proceed to ASCT, there is an assessment of the cardiac, renal fonction, comorbidities\n",
      "<class 'str'>\n",
      "Neurotoxicity has not been a significant issue in any of these MM CARÂ T-cell trials, \n",
      "<class 'str'>\n",
      "do not have any clinical trials for triple or penta refractory MM\n",
      "<class 'str'>\n",
      "CAR-T is not going to be a mainstay therapy in BCMA\n",
      "<class 'str'>\n",
      "it?s extremely reassuring and refreshing to see validation of new immunotherapy targets for treating MM\n",
      "<class 'str'>\n",
      "She anticipates good response in the monotherapy arm\n",
      "<class 'str'>\n",
      "caution should be used when sequencing CAR-T and T-cell bispecifics \n",
      "<class 'str'>\n",
      "Tere is a need of QoL data specialy for patient treated in early line.\n",
      "<class 'str'>\n",
      "combination with pomalidomide will be a much better choice\n",
      "<class 'str'>\n",
      "would like BCMA trials for consolidation in pts\n",
      "<class 'str'>\n",
      "Using minimal residual disease as a way of deciding which patients can safely afford a treatment holiday\n",
      "<class 'str'>\n",
      "CART in MM is difficult because there are many hurdles to get a patient to therapy such as good insurance\n",
      "<class 'str'>\n",
      "FIRST trial is used to determine the treatment\n",
      "<class 'str'>\n",
      "considering recently approved and upcoming therapies, needs to see all data\n",
      "<class 'str'>\n",
      "MM-3 is being highlighted as a trial of interest for BCMA-exposed patients\n",
      "<class 'str'>\n",
      " efficacy and safety data looks like before suggesting more trial designs\n",
      "<class 'str'>\n",
      "If there was a washout, he'd use a BCMA therapy or clinical trial to bridge.Â  \n",
      "<class 'str'>\n",
      "important to determine the sequence of the treatment targeting BCMA\n",
      "<class 'str'>\n",
      "Daratumumab is prescribed in 1st line. In combination with VRd \n",
      "<class 'str'>\n",
      "generate more data which shows the importance of MRD to determine the choice of treatment\n",
      "<class 'str'>\n",
      "frustrated that they are required to repeat training that they previously completed\n",
      "<class 'str'>\n",
      "DRD (based on Maya trial) is best treatment option\n",
      "<class 'str'>\n",
      "Targeting BCMA without ocular toxicity and less neurotoxicity\n",
      "<class 'str'>\n",
      "Largest barrier of including minorities in trials and getting them equal treatment opportunity for MM is the rural/urban dichotomy.\n",
      "<class 'str'>\n",
      "if the patient has renal issues, he gives DARA/POM/dex.Â Â \n",
      "<class 'str'>\n",
      "transgene (2 CARs) mechanism that binds BCMA in different spots\n",
      "<class 'str'>\n",
      "large need for trials in earlier lines\n",
      "<class 'str'>\n",
      "Isa-based regimens due to the need for more supportive care\n",
      "<class 'str'>\n",
      "waiting to see more QOL data for SQ daratumumab before exploring\n",
      "<class 'str'>\n",
      "priming the patient for a more severe neuropathy AE\n",
      "<class 'str'>\n",
      "BCMA bispecific therapy in second transplant patients would be straightforward \n",
      "<class 'str'>\n",
      "rechallenging a daratumumab-refractory patient with Isatuximab\n",
      "<class 'str'>\n",
      "reducing the requirement for a 6 month \"dara holiday\n",
      "<class 'str'>\n",
      "refers all relapse MM patients to primary center\n",
      "<class 'str'>\n",
      "triplet (RVD or CyBorD) for transplant-eligible pts\n",
      "<class 'str'>\n",
      "more data to prove the interest of those molecules in 2nd or 1st ine\n",
      "<class 'str'>\n",
      "heme/ oncs should pay attention\n"
     ]
    }
   ],
   "source": [
    "for i in l:\n",
    "    print(type(i))\n",
    "    print(i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Function to convert  \n",
    "def listToString(s): \n",
    "    \n",
    "    # initialize an empty string\n",
    "    str1 = \" \" \n",
    "    \n",
    "    # return string  \n",
    "    return (str1.join(s))\n",
    "        \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "sequence item 0: expected str instance, float found",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-28-8204d95368ab>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[1;32m----> 1\u001b[1;33m \u001b[0mlis1\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mlistToString\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mimp_sen1\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m<ipython-input-27-feaf9c3675e0>\u001b[0m in \u001b[0;36mlistToString\u001b[1;34m(s)\u001b[0m\n\u001b[0;32m      6\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      7\u001b[0m     \u001b[1;31m# return string\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 8\u001b[1;33m     \u001b[1;32mreturn\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mstr1\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0ms\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m      9\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     10\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mTypeError\u001b[0m: sequence item 0: expected str instance, float found"
     ]
    }
   ],
   "source": [
    "lis1=listToString(imp_sen1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "100\n",
      "bi-specific data is looking much better\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['bi-specific data is looking much better']"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dfo= ''' HCP does not feel like the data are all that impressive for CAR-T and the bi-specific data is looking much better.'''\n",
    "imp_sentence_list =l\n",
    "get_similarity_score(dfo, imp_sentence_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df_1 =final_df.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "data['Important senctences'] = data[\"DFO Description\"].apply(lambda x : get_similarity_score(x, imp_sentence_list=l))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df_1.to_csv('final_file.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "36\n",
      "36\n",
      "34\n",
      "33\n",
      "32\n",
      "23\n",
      "28\n",
      "38\n",
      "28\n",
      "35\n",
      "41\n",
      "42\n",
      "43\n",
      "37\n",
      "39\n",
      "37\n",
      "33\n",
      "49\n",
      "36\n",
      "26\n",
      "33\n",
      "36\n",
      "34\n",
      "47\n",
      "33\n",
      "39\n",
      "41\n",
      "32\n",
      "69\n",
      "30\n",
      "31\n",
      "34\n",
      "34\n",
      "100\n",
      "46\n",
      "29\n",
      "30\n",
      "36\n",
      "38\n",
      "34\n",
      "32\n",
      "40\n",
      "32\n",
      "40\n",
      "33\n",
      "37\n",
      "31\n",
      "30\n",
      "35\n",
      "36\n",
      "20\n",
      "34\n",
      "37\n",
      "43\n",
      "39\n",
      "48\n",
      "40\n",
      "33\n",
      "37\n",
      "33\n",
      "34\n",
      "48\n",
      "42\n",
      "36\n",
      "32\n",
      "25\n",
      "36\n",
      "35\n",
      "38\n",
      "38\n",
      "42\n",
      "28\n",
      "38\n",
      "31\n",
      "32\n",
      "36\n",
      "35\n",
      "40\n",
      "43\n",
      "28\n",
      "38\n",
      "39\n",
      "33\n",
      "34\n",
      "31\n",
      "43\n",
      "33\n",
      "35\n",
      "32\n",
      "30\n",
      "27\n",
      "33\n",
      "31\n",
      "36\n",
      "26\n",
      "37\n",
      "27\n",
      "42\n",
      "35\n",
      "29\n",
      "42\n",
      "27\n",
      "39\n",
      "28\n",
      "38\n",
      "33\n",
      "16\n",
      "37\n",
      "35\n",
      "34\n",
      "32\n",
      "30\n",
      "35\n",
      "56\n",
      "34\n",
      "42\n",
      "48\n",
      "16\n",
      "33\n",
      "29\n",
      "37\n",
      "35\n",
      "41\n",
      "25\n",
      "40\n",
      "32\n",
      "36\n",
      "37\n",
      "30\n",
      "48\n",
      "31\n",
      "38\n",
      "36\n",
      "31\n",
      "67\n",
      "34\n",
      "29\n",
      "30\n",
      "35\n",
      "18\n",
      "31\n",
      "38\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "100\n",
      "100\n",
      "0\n",
      "0\n",
      "100\n",
      "100\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "0\n",
      "44\n",
      "41\n",
      "38\n",
      "35\n",
      "38\n",
      "30\n",
      "33\n",
      "38\n",
      "35\n",
      "43\n",
      "39\n",
      "44\n",
      "39\n",
      "35\n",
      "37\n",
      "34\n",
      "34\n",
      "34\n",
      "38\n",
      "30\n",
      "45\n",
      "35\n",
      "37\n",
      "28\n",
      "35\n",
      "43\n",
      "28\n",
      "33\n",
      "48\n",
      "41\n",
      "38\n",
      "41\n",
      "36\n",
      "33\n",
      "43\n",
      "34\n",
      "30\n",
      "36\n",
      "40\n",
      "39\n",
      "41\n",
      "40\n",
      "39\n",
      "42\n",
      "38\n",
      "33\n",
      "31\n",
      "100\n",
      "35\n",
      "45\n",
      "33\n",
      "34\n",
      "33\n",
      "47\n",
      "33\n",
      "40\n",
      "33\n",
      "33\n",
      "32\n",
      "37\n",
      "40\n",
      "43\n",
      "40\n",
      "44\n",
      "39\n",
      "33\n",
      "42\n",
      "48\n",
      "29\n",
      "34\n",
      "38\n",
      "41\n",
      "38\n",
      "41\n",
      "34\n",
      "36\n",
      "43\n",
      "27\n",
      "47\n",
      "31\n",
      "49\n",
      "39\n",
      "38\n",
      "32\n",
      "33\n",
      "41\n",
      "29\n",
      "42\n",
      "34\n",
      "36\n",
      "35\n",
      "42\n",
      "44\n",
      "42\n",
      "32\n",
      "43\n",
      "38\n",
      "45\n",
      "40\n",
      "39\n",
      "39\n",
      "32\n",
      "46\n",
      "33\n",
      "40\n",
      "36\n",
      "23\n",
      "27\n",
      "52\n",
      "26\n",
      "38\n",
      "41\n",
      "40\n",
      "47\n",
      "48\n",
      "36\n",
      "44\n",
      "34\n",
      "29\n",
      "40\n",
      "39\n",
      "28\n",
      "37\n",
      "40\n",
      "38\n",
      "42\n",
      "37\n",
      "42\n",
      "43\n",
      "48\n",
      "36\n",
      "40\n",
      "44\n",
      "32\n",
      "67\n",
      "30\n",
      "36\n",
      "36\n",
      "56\n",
      "35\n",
      "42\n",
      "41\n",
      "42\n",
      "27\n",
      "28\n",
      "29\n",
      "38\n",
      "32\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-87-1911db336367>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      3\u001b[0m     \u001b[1;32mfor\u001b[0m \u001b[0ma\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mfinal_list\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 5\u001b[1;33m         \u001b[0mx\u001b[0m \u001b[1;33m=\u001b[0m\u001b[0mfuzz\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mpartial_ratio\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mi\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0ma\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m      6\u001b[0m         \u001b[0mprint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mx\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      7\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mx\u001b[0m\u001b[1;33m>\u001b[0m\u001b[1;36m90\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\site-packages\\fuzzywuzzy\\utils.py\u001b[0m in \u001b[0;36mdecorator\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m     36\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m \u001b[1;32mor\u001b[0m \u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     37\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 38\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mfunc\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     39\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mdecorator\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     40\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\site-packages\\fuzzywuzzy\\utils.py\u001b[0m in \u001b[0;36mdecorator\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m     27\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;33m==\u001b[0m \u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     28\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[1;36m100\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 29\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mfunc\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     30\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mdecorator\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     31\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\site-packages\\fuzzywuzzy\\utils.py\u001b[0m in \u001b[0;36mdecorator\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m     45\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m==\u001b[0m \u001b[1;36m0\u001b[0m \u001b[1;32mor\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m==\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     46\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 47\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mfunc\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     48\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mdecorator\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     49\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\site-packages\\fuzzywuzzy\\fuzz.py\u001b[0m in \u001b[0;36mpartial_ratio\u001b[1;34m(s1, s2)\u001b[0m\n\u001b[0;32m     60\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     61\u001b[0m         \u001b[0mm2\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mSequenceMatcher\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mshorter\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mlong_substr\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 62\u001b[1;33m         \u001b[0mr\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mm2\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mratio\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     63\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mr\u001b[0m \u001b[1;33m>\u001b[0m \u001b[1;36m.995\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     64\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[1;36m100\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\difflib.py\u001b[0m in \u001b[0;36mratio\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    642\u001b[0m         \"\"\"\n\u001b[0;32m    643\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 644\u001b[1;33m         \u001b[0mmatches\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0msum\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtriple\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;33m-\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mtriple\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget_matching_blocks\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    645\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0m_calculate_ratio\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mmatches\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0ma\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m+\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mb\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    646\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\difflib.py\u001b[0m in \u001b[0;36mget_matching_blocks\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    477\u001b[0m         \u001b[1;32mwhile\u001b[0m \u001b[0mqueue\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    478\u001b[0m             \u001b[0malo\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mahi\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mblo\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mbhi\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mqueue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mpop\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 479\u001b[1;33m             \u001b[0mi\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mj\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mk\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mx\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mfind_longest_match\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0malo\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mahi\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mblo\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mbhi\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    480\u001b[0m             \u001b[1;31m# a[alo:i] vs b[blo:j] unknown\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    481\u001b[0m             \u001b[1;31m# a[i:i+k] same as b[j:j+k]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\lib\\difflib.py\u001b[0m in \u001b[0;36mfind_longest_match\u001b[1;34m(self, alo, ahi, blo, bhi)\u001b[0m\n\u001b[0;32m    408\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0mj\u001b[0m \u001b[1;33m>=\u001b[0m \u001b[0mbhi\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    409\u001b[0m                     \u001b[1;32mbreak\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 410\u001b[1;33m                 \u001b[0mk\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mnewj2len\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mj\u001b[0m\u001b[1;33m]\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mj2lenget\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mj\u001b[0m\u001b[1;33m-\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m+\u001b[0m \u001b[1;36m1\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    411\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0mk\u001b[0m \u001b[1;33m>\u001b[0m \u001b[0mbestsize\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    412\u001b[0m                     \u001b[0mbesti\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mbestj\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mbestsize\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mi\u001b[0m\u001b[1;33m-\u001b[0m\u001b[0mk\u001b[0m\u001b[1;33m+\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mj\u001b[0m\u001b[1;33m-\u001b[0m\u001b[0mk\u001b[0m\u001b[1;33m+\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mk\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "\n",
    "for i in final_df['DFO Description']:\n",
    "    my_lis =[]\n",
    "    for a in final_list:\n",
    "        \n",
    "        x =fuzz.partial_ratio(i, a)\n",
    "        print(x)\n",
    "        if x>90:\n",
    "            my_lis.append(a)\n",
    "            \n",
    "    \n",
    "            \n",
    "            \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
